Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA II: Industry Shares Stage With FDA

Executive Summary

Public meeting departs from usual format, allowing industry representatives to sit next to FDA and answer audience questions as generic during user fee agreement outlined.


Related Content

Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'
Biosimilar Guidance Development Timelines Criticized By Docs And Patients
Generic Drug User Fees Will Jump More Than 50% In FY 2018





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts